Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126556441 | 12655644 | 1 | I | 20140912 | 20160816 | 20160816 | PER | US-ROCHE-1628685 | ROCHE | 0.00 | F | Y | 0.00000 | 20160816 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126556441 | 12655644 | 1 | PS | PEGASYS | PEGINTERFERON ALFA-2A | 1 | Subcutaneous | 180 MCG SQ WEEKLY | U | 103964 | SOLUTION FOR INJECTION | ||||||||
| 126556441 | 12655644 | 2 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | DAILY IN TWO DIVIDED DOSES | U | 21511 | TABLET | ||||||||
| 126556441 | 12655644 | 3 | SS | SOVALDI | SOFOSBUVIR | 1 | Oral | DAILY | U | 0 | 400 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126556441 | 12655644 | 1 | Chronic hepatitis C |
| 126556441 | 12655644 | 2 | Chronic hepatitis C |
| 126556441 | 12655644 | 3 | Chronic hepatitis C |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126556441 | 12655644 | Abdominal pain | |
| 126556441 | 12655644 | Fatigue |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |